Bavarian Nordic Sustainability Profile
Bavarian Nordic A/S, a leading biotechnology company headquartered in Denmark (DK), is renowned for its innovative approach in the field of immunotherapy and vaccine development. Founded in 1994, the company has made significant strides in combating infectious diseases and cancer, with a strong operational presence across Europe and North America. Specialising in the development of live virus vaccines and immunotherapies, Bavarian Nordic's core products include the smallpox vaccine, IMVAMUNE®, and the cancer immunotherapy candidate, BN-Brachyury. These offerings are distinguished by their unique mechanisms and robust safety profiles, positioning the company as a key player in the biopharmaceutical industry. With a commitment to advancing public health, Bavarian Nordic has achieved notable milestones, including partnerships with global health organisations, solidifying its reputation as a trusted innovator in vaccine technology.
DitchCarbon Score
How does Bavarian Nordic's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bavarian Nordic's score of 44 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bavarian Nordic's reported carbon emissions
In 2023, Bavarian Nordic reported total carbon emissions of approximately 10,682,000 kg CO2e, comprising 4,364,000 kg CO2e from Scope 1 and 6,318,000 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data. Bavarian Nordic is committed to achieving Net Zero emissions by 2050, in alignment with the Paris Agreement. In the near term, the company plans to define its carbon footprint reduction pathway in 2024, focusing on comprehensive strategies to reduce emissions across all scopes. This commitment reflects their dedication to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. The emissions data is not cascaded from any parent organization, indicating that Bavarian Nordic independently reports its carbon footprint. The company is headquartered in Denmark (DK) and continues to work towards its climate commitments while monitoring its emissions performance.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - |
How Carbon Intensive is Bavarian Nordic's Industry?
How Carbon Intensive is Bavarian Nordic's Location?
Bavarian Nordic's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bavarian Nordic has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Bavarian Nordic's sustainability data and climate commitments